<DOC>
	<DOCNO>NCT02916355</DOCNO>
	<brief_summary>Role IL-1 postprandial fatigue - The Chäschüechli 2 Study It randomize , single dose , placebo-controlled , double blind , cross-over , proof-of-concept study . 16 healthy young men include study . The objective study evaluate severity postprandial fatigue drive IL-1 . Since fatigue associate increased cytokine level , since fatigue chronic inflammatory setting , type 2 diabetes , reduce inhibition IL-1β , postprandial fatigue might also respond anti-inflammatory intervention IL-1 inhibition . The aim study investigate whether postprandial fatigue , least part , drive IL-1 system .</brief_summary>
	<brief_title>Role Interleukin ( IL ) -1 Postprandial Fatigue - The Chäschüechli 2 Study</brief_title>
	<detailed_description />
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Male subject nonsmoking apparently healthy BMI &gt; 18 ≤28 kg/m2 BMI &gt; 30 ≤35 kg/m2 Age 2065 year Subject usually eat breakfast lunch Willingness use contraceptive measure adequate prevent subject 's partner become pregnant study . Adequate contraceptive measure include hormonal method use two cycle prior screen ( e.g. , oral contraceptive pill , contraceptive patch , contraceptive vaginal ring ) , double barrier method ( e.g. , contraceptive sponge , diaphragm use conjunction contraceptive foam jelly , condom use conjunction contraceptive foam jelly ) , intrauterine method ( IUD ) sterilization ( e.g. , tubal ligation monogamous relationship vasectomize partner ) . Owner smartphone able download use sleep APP , Sleep cycle , prior study day . Subjects exclude study meet follow criterion : Night shift worker Subjects suffer sleep disturbance Clinical sign infection week inclusion history infection last 2 month ( CRP &gt; 5mg/l ) Impaired fast glucose ( fast plasma glucose &gt; 5.5mmol/l ) Hematologic disease ( leukocyte count &lt; 1.5x109/l , hemoglobin &lt; 11 g/dl , platelet &lt; 100 x 103/ul ) Kidney disease ( creatinine &gt; 1.5 mg/dl ) ) Liver disease ( transaminases &gt; 2x upper normal range ) Heart disease Pulmonary disease Inflammatory disease History carcinoma History tuberculosis Alcohol consumption &gt; 40g/d Smoking Known allergy towards Kineret Known allergy ingredient test meal Current treatment drug week inclusion , include vitamin supplementation ( especially vitamin C E ) Use investigational drug within 30 day prior enrolment within 5 halflives investigational drug , whichever longer Subject refuse unable give write informed consent</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>